Resunab, Potential Scleroderma Treatment, Shows Ability to Stop Inflammation in Early Clinical Trial
Corbus Pharmaceuticals reported new findings supporting the anti-inflammatory actions of its lead compound Resunab (JBT-101), which is currently being explored in a clinical trial for scleroderma. Data from experiments in healthy volunteers showed that Resunab prevented the infiltration of immune cells, called neutrophils, and changed blood flow in a…